Publications by authors named "Maria Teresa Otero-Barros"
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Hum Vaccin Immunother
December 2024
Article Synopsis
- Nirsevimab has been approved for universal RSV prevention in infants, with a study (NIRSE-GAL) launched in Galicia in September 2023 to assess its effectiveness against various RSV-related health issues.
- The study will monitor infants during the RSV season, focusing on different groups including newborns and those at high risk, and will track outcomes until significant events occur or the study concludes.
- Data analysis will utilize sophisticated models and will include safety monitoring of nirsevimab, with results communicated through scientific publications and conferences.
Article Synopsis
- Galicia, Spain, launched a program in September 2023 to give nirsevimab for RSV prevention in infants, focusing on newborns, those under 6 months, and high-risk children aged 6-24 months.
- The interim analysis of the study, using data from Sept 25 to Dec 31, 2023, assesses nirsevimab's effectiveness in preventing different levels of RSV-related hospitalizations and complications.
- The study compares the results with data from previous RSV seasons to calculate how many cases of hospitalization were potentially avoided due to the immunization campaign.
Article Synopsis
- The study investigates the impact of respiratory syncytial virus (RSV) on infants, highlighting that the effects go beyond just hospitalization and require better understanding for future healthcare planning.
- Researchers analyzed data from 6626 children, comparing those hospitalized with severe RSV to those who weren't, focusing on healthcare visits and prescriptions related to respiratory issues.
- Results showed that severe RSV significantly increased visits to primary healthcare for conditions like wheezing and lower respiratory infections, indicating a substantial burden even after initial hospitalization.
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design.
View Article and Find Full Text PDFBackground: Studies on vaccine effectiveness (VE) against COVID-19 in the pediatric population are outgoing. We aimed to quantify VE against SARS-CoV-2 in two pediatric age groups, 5-11 and 12-17-year-old, while considering vaccine type, SARS-CoV-2 variant, and duration of protection.
Methods: A population-based test-negative control study was undertaken in Galicia, Spain.
Background: Research on the effectiveness of COVID-19 booster-based vaccine schedule is ongoing and real-world data on vaccine effectiveness (VE) in comorbid patients are limited. We aimed to estimate booster dose VE against SARS-CoV-2 infection and COVID-19 severity in the general population and in comorbid patients.
Method: A retrospective test-negative control study was undertaken in Galicia-Spain (December 2020-November 2021).
Objectives: To know the impact of COVID-19 in incidence and lethality in nursing homes in Galicia.
Methods: This is a descriptive study of nursing homes residents and workers with confirmed COVID-19. The analysis spanned from March 1, 2020 to March 27, 2022, stratified into 6 periods (one per wave).
During June 2022, Spain was one of the countries most affected worldwide by a multicountry monkeypox outbreak with chains of transmission without identified links to disease-endemic countries. We provide epidemiologic features of cases reported in Spain and the coordinated measures taken to respond to this outbreak.
View Article and Find Full Text PDFEvaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain.
Int J Environ Res Public Health
March 2022
Investigating vaccine effectiveness (VE) in real-world conditions is crucial, especially its variation across different settings and populations. We undertook a test-negative control study in Galicia (Northwest Spain) to assess BNT162b2 effectiveness against acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as well as COVID-19 associated hospitalization, intensive care unit (ICU) admission and mortality. A total of 44,401 positive and 817,025 negative SARS-CoV-2 test results belonging to adults were included.
View Article and Find Full Text PDF